Welcome

Sign out Have a question? We're here to help

Copyright © 2019 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Madrigal Pharmaceuticals Inc (MDGL)

$95.24 0.32 (0.34%)

16:53 EDT MDGL Stock Quote Delayed 15 Minutes

Volume:

Previous Close $95.24

Market Cap 1.36B

PE Ratio -38.25

EPS -2.49

Volume (Avg. Vol.) 134,200

Day's Range 92.67 - 95.24

52-Week Range 89.83 - 292.29

Dividend & Yield N/A (N/A)

MDGL Stock Predictions, Articles, and Madrigal Pharmaceuticals Inc News

From InvestorPlace
From the Web

5 Biotech Stocks to Play the Sector’s Next Big Trend: NASH

By Aaron Levitt, InvestorPlace Contributor Sep 26, 2018

Looking for blockbuster potential? These five biotech stocks may have found it in treating NASH -- an untapped market of up to $35 billion.

4 Biotech Stocks With Leaky Pipelines

By Regina Borsellino Apr 10, 2018

A strong pipeline can make or break biotech stocks, ensuring strong profits for years to come. These four biotech companies don't make the cut.

New President of R&D at Madrigal Pharma

From Seeking Alpha Jul 11, 2019

Madrigal Pharmaceuticals (NASDAQ:MDGL) has promoted Rebecca Taub, M.D., to the newly created positon of President of R&D.Dr. Taub has served as Chief Medical Officer and Executive VP of R&D,

Notable Monday Option Activity: LULU, ULTA, MDGL

From Market News Video Jul 8, 2019

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in lululemon athletica inc (LULU), where a total of 16,220 contracts have traded so far, representing approximately 1.6 million underlying shares. That amounts to about 55.2% of LULU's average daily trading volume over the past month of 2.9 million shares..

H.C. Wainwright Reaffirms Their Buy Rating on Madrigal Pharmaceuticals Inc (MDGL)

From Smarter Analyst Jul 3, 2019

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Madrigal Pharmaceuticals Inc (MDGL), with a price target of $225. The

H.C. Wainwright Reaffirms Their Buy Rating on Madrigal Pharmaceuticals Inc (MDGL)

From Analyst Ratings Jul 3, 2019

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Madrigal Pharmaceuticals Inc (MDGL – Research Report), with a price target of $225. The company’s shares closed yesterday at $103.17, close to its 52-week low of $89.83. Arce said: “We are confident that the MAESTRO-NASH trial is well-managed: it is

Madrigal Pharmaceuticals Inc (MDGL) Initiated with a Hold at Stifel Nicolaus

From Smarter Analyst Jun 24, 2019

Stifel Nicolaus analyst Derek Archila initiated coverage with a Hold rating on Madrigal Pharmaceuticals Inc (MDGL) today and set a price target of $126.

Madrigal Pharmaceuticals Inc (MDGL) Initiated with a Hold at Stifel Nicolaus

From Analyst Ratings Jun 24, 2019

Stifel Nicolaus analyst Derek Archila initiated coverage with a Hold rating on Madrigal Pharmaceuticals Inc (MDGL – Research Report) today and set a price target of $126. The company’s shares opened today at $104.82, close to its 52-week low of $89.83. Archila wrote: “We believe resmetirom’s Phase 2b data are encouraging on NASH resolution and

Navellier Ratings

Powered by Portfolio Grader

Total Grade

F

Strong Sell

Free Report

10 Stocks Set for Monster Growth

He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!

Download your FREE COPY!